Savara(US:SVRA) Prnewswire·2025-09-25 12:45Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Savara Inc. regarding a class action lawsuit due to alleged misleading statements related to the approval of the MOLBREEVI BLA treatment for pulmonary alveolar proteinosis [1][2]. Group 1: Allegations and Class Period - The class period for the allegations is from March 4, 2024, to May 23, 2025 [1]. - Allegations include that Savara Inc. made materially false and misleading statements about the MOLBREEVI BLA, specifically regarding its chemistry, manufacturing, and controls [1]. - It is claimed that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which could delay the submission timeline previously communicated to investors [1]. Group 2: Impact on Shareholders - The delay in regulatory approval may increase the likelihood that Savara would need to raise additional capital [1]. - Shareholders are encouraged to register for the class action to monitor the case's progress and potentially seek lead plaintiff status by the deadline of November 7, 2025 [2]. Group 3: Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices [3]. - The firm seeks recovery for investors who suffered losses due to the alleged false and misleading statements that inflated the company's stock price [3].